1221492-53-0

Basic information

• Product Name: N,N'-bis(benzyloxycarbonyl)-2-(S)-hydroxy-4-guanidino-butyric acid
• Synonyms: N,N'-bis(benzyloxycarbonyl)-2-(S)-hydroxy-4-guanidino-butyric acid
• CAS NO: 1221492-53-0
• Molecular Weight: 429.43
• Mol File: 1221492-53-0.mol
• Article Data: 8

Chemical Properties

• CAS DataBase Reference: N,N'-bis(benzyloxycarbonyl)-2-(S)-hydroxy-4-guanidino-butyric acid(CAS DataBase Reference)
• NIST Chemistry Reference: N,N'-bis(benzyloxycarbonyl)-2-(S)-hydroxy-4-guanidino-butyric acid(1221492-53-0)
• EPA Substance Registry System: N,N'-bis(benzyloxycarbonyl)-2-(S)-hydroxy-4-guanidino-butyric acid(1221492-53-0)

Safety Data

• Hazardous Substances Data: 1221492-53-0(Hazardous Substances Data)

Upstream product

• 3938-83-8 (S)-4-amino-2-hydroxybutanoic acid 
• 152120-55-3 N,N-bis(benzyloxycarbonyl)-1H-pyrazole-1-carboxamidine 

Relevant articles and documents

ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS

Compounds having antibacterial activity are disclosed. The compounds have the following structure (I) including stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, wherein Q1, Q2, Q5, R1, R2, R3, Z1 and Z2 are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.

ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS

Compounds having antibacterial activity are disclosed. The compounds have the following structure (I): (Formula (I)), including stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, wherein Q1, Q2, R1, R2, R3, Z1 and Z2 are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.

ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS

Compounds having antibacterial activity are disclosed. The compounds have one of the following structures (I) or (II): including stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, wherein Q1, Q2, R1, R2, R3 and Z1 are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.